Regula Launches Full Support for Digital Travel Credentials in Latest Software Update
15.1.2025 08:00:00 CET | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, has updated its Regula Document Reader SDK. Now, the software fully supports the new Digital Travel Credential (DTC) format, aligned with the International Civil Aviation Organization (ICAO) standards. This enhancement enables governments, airlines, and border control authorities worldwide to process travel documents with unmatched security, efficiency, and ease—whether on-site or remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115990355/en/

With Regula Document Reader SDK, travelers can create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document like ePassport. (Graphic: Regula)
The DTC is a secure digital solution that streamlines travel experiences. It consolidates key personal information into a single virtual document that travelers can store on their mobile devices or upload to their digital wallets and share whenever needed. The main goal of the DTC is to facilitate clearance procedures during travel and ensure that people are eligible to enter their destination before they board a flight.
The ICAO has defined three types of DTC, each offering varying levels of convenience and security for travelers.
- DTC Type 1 allows travelers to create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document, stored on their personal device. However, travelers must still carry the original document for identity verification.
- DTC Type 2, issued by authorities, combines a cryptographically linked Virtual Component (DTC-VC) and a Physical Component (DTC-PC). This format adds an extra layer of security while maintaining a connection to the physical document.
- DTC Type 3 represents the future of travel identification: a fully digital document issued directly by authorities. Unlike the other types, it eliminates the need for a physical ID, streamlining identity verification for a completely digital experience.
Now, with Regula Document Reader SDK, users can create and reprocess DTC-VC from ePassports, and verify it by passing DTC-VC data as input. Also, support for handling DTC-PC has been introduced. The updated Regula Document Reader SDK can:
- read the document’s RFID chip with a smartphone or passport reader and create DTC-VC;
- recognize, read, and verify DTC-VC with a smartphone, passport reader, or server;
- read DTC-PC with a smartphone or passport reader, parse its data, and verify it.
The updated Regula Document Reader SDK is equipped with advanced features that fully support DTC implementation.
- Trustworthy NFC verification. First and foremost, it provides trusted server-side NFC verification of the ID so it ensures accurate and trustworthy DTC-VC creation. Since all the data from the chip can be verified on a secure server, there is no need to question the reliability of the checks performed by a mobile device (which is prone to manipulation). Such an approach ensures that the virtual component of a traveler’s document is secure and taken from an authentic ID.
- Compliance with ICAO guidelines and technical reports. Regula Document Reader SDK not only verifies DTCs but also guarantees that each DTC fully complies with ICAO guidelines and technical reports. This makes Regula’s solution an indispensable tool for airlines and governments so they can be confident in the validity of travelers’ DTCs.
- Future-ready technology. In addition to supporting DTC-VC, Regula’s technology is fully compatible with handling DTC-PC. Looking further ahead, Regula is ready to process DTC Type 3, a digital passport that is expected in the next several years.
To facilitate the fast and smooth global application of DTCs, Regula Document Reader SDK relies on the most comprehensive identity document template database, which is owned and maintained by Regula. Currently, it contains more than 14,000 ID templates from 251 countries and territories, and it’s constantly growing.
Regula Document Reader SDK is designed for easy integration into third-party applications, allowing clients to incorporate this advanced DTC-ready technology seamlessly into their existing systems. With customizable options, businesses can adapt the solution to meet their unique operational requirements while providing end users with a secure, streamlined digital experience.
“We see that the world is rapidly moving to embrace digital IDs. According to the Forrester Consulting study commissioned by Regula earlier in 2024, nearly half of businesses around the world, 42%, are actively integrating digital IDs into their systems. For the Aviation sector, this rate is even higher: 50%. By ensuring full DTC support in the latest update of Regula Document Reader SDK, we are helping our clients to smoothly transition to the future of travel, where secure, digital-first solutions redefine the passenger experience,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the capabilities of the updated Regula Document Reader SDK, read the release documentation on Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification. Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115990355/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom